Insights
Insights From Our Experts
Articles
Do Germany’s New Hemophilia Regulations Have Wider-Reaching Implications?
In July 2019, the Drug Safety and Supply Law (GSAV) was passed by Germany’s Higher Chamber of Parliament, bringing about substantial changes to Germany’s health policy. Besides introducing new strategies for biosimilar uptake and cell and…
Four Ways Predictive Analytics Can Strengthen Your Commercialization Efforts
Over the past few years, artificial intelligence (AI) and machine learning (ML) have been trending topics in healthcare but are now being propelled to the forefront of clinical decision support and care delivery. Some organizations, however,…
Optimizing the Performance of a PSP and Improving Outcomes For All Stakeholders
Patient Support Programs (PSP) have been proven to improve clinical and patient outcomes and help manage patient out-of-pocket cost and prescribed use. Particularly for specialty drugs, the services provided under the PSP umbrella not only help…
ODRD Insights: Building an AI-Driven Data Ecosystem to Drive Commercial Activities
The market landscape, especially for rare diseases, is dynamic and presents a unique set of challenges for the life sciences industry. Unlike the case for broader disease states, most rare disease patients are not correctly diagnosed…
The U.S. Pharma Market Outlook: Path to Recovery and the New Normal
With the U.S. presidential election days away and the continued impact of a pandemic, EVERSANA and Reuters gathered industry leaders to discuss what is to come. Watch as the panel discusses the tough questions facing pharma,…
NORD 2020 Insights: Entering a New Era
EVERSANA was a proud sponsor of the 2020 NORD Rare Diseases & Orphan Products Breakthrough Summit to advance the dialogue on ways to improve the lives of over 25 million Americans living with rare diseases. Our…
Unlock Europe To Create Value
Posted on October 22, 202010/22/20
The European Union (EU) is the second largest pharma market in the world and represents a major opportunity for U.S. biotechnology companies. Due to the perceived complexity of launching in Europe, many biotech companies licence their…
MARKET ACCESS AND TREATMENT OUTCOMES: Shifting From the Volume of Data to the Value of Insights
From Volume to Value: “The best prescription is insightful knowledge.” Former Surgeon General of the United States Dr. C. Everett Koop once aphoristically said, “The best prescription is knowledge.” This thought permeates much of what drives…
Population Health Partnerships To Advance Value-Based Care
Posted by
Dr. Richard Stefanacci on October 20, 202010/20/20
The business model for health care in the United States is evolving from a volume-driven model to a consumer-centric, value-driven model. As such, there are new competencies required of hospitals and health systems to effectively manage…
Mitigating Risk: When A Curveball Threatens Your Product’s Launch
In this 3-minute video, Mike DeLaroche shares a new commercialization model that mitigates risk and combats curveballs that manufacturers cannot predict when launching products.